Kornimate/medical-research-clean huggingface dataset:
combined 25-gauge vitrectomy and cataract surgery with toric intraocular lens with idiopathic epiretinal membrane.

Conditions: Cataract; Epiretinal Membrane; Corneal Astigmatism

Summary: toric intraocular lens (iol) is now widely used for the cataract surgery with preoperative corneal astigmatism. symptomatic epiretinal membrane (erm) is often treated with 25-gauge transconjunctival sutureless vitrectomy, resulting in good visual recovery. so far, however, limited information is available on the the stability of axis rotation, astigmatism correction, and improvement in uncorrected distance visual acuity, using astigmatism-correcting iol in a 25-gauge transconjunctival sutureless vitrectomy combined with cataract surgery. in the current study, eyes with a preoperative corneal cylinder of more than 0.75 diopter had a triple procedure for idiopathic erm using a toric iol. outcome measures will be the amount of iol axis rotation, uncorrected visual acuity, corrected distance visual acuity, and corneal and refractive astigmatism up to 6 months postoperatively. we are expecting to show that postoperative iol axis stability is similar to that reported for cataract surgery alone in vitrectomy (triple procedure) for idiopathic erm with a toric iol.


Eligibility criteria:
inclusion criteria: * preoperative corneal cylinder of more than 0.75 diopter * symptomatic idiopathic epiretinal membrane * symptomatic cataract exclusion criteria: * severe media opacity other cataract * eyes with other retinal disease, such as diabetic retinopathy, retinal vein occlusion, rhegmatogenous retinal detachment
randomised trial of nbi for adenoma detection

Conditions: Adenomas

Summary: does a new colonoscopic viewing technique called narrow band imaging (nbi) help doctors detect more patients with at least one pre-cancerous polyp (adenoma) than conventional colonoscopy using white light alone? may 2007 protocol minor amendment: additional viewing by endoscopists outside st mark's ro allow assessment of inter- and intra-observer variability.

colorectal cancer is the second commonest cause of cancer death. in a majority of cases it is preceded by a precancerous lesion called an adenoma (polyp). detection and removal of adenomas at colonoscopy has been shown to reduce the death rate from colorectal cancer. however, despite meticulous examination there is a "miss rate" for adenomas at colonoscopy which ranges from 66-25% in back-to-back colonoscopy studies. the nature of the polyps which as well as being pedunculated (cherry like) can be flat or depressed making them difficult to see, which may contribute to the "miss rate". the factors, which influence the endoscopist detection are not well studied. polyp detection rates wary widely, even among experts. techniques that highlight lesions have advanced in recent years. chromoendoscopy, the current gold standard technique, relies on spraying dye on the bowel lining, has been shown to help pick up more pre-cancerous polyps in two of three studies; however it is not widely used as it is time consuming and requires extra equipment and training. narrow band imaging (nbi) is a technique that relies in light filters to improve contrast for the smallest blood vessels in the bowel lining which shows up adenomas as they have a richer vascular network. it is sometimes described as "digital chromoendoscopy" as the images produced are similar to chromoendoscopy, but it is much simpler and quicker to use. autofluorescence endoscopy uses short wavelength light and light filters to produce a false colour image of the bowel lining where polyps stand out. these techniques have been used with some success in the oesophagus and stomach but little work is available for the colon. we aim to see if nbi is better than standard colonoscopy for detecting precancerous polyps. this is likely as it is similar to chromoendoscopy which is already shown to help. if a polyp is found we will use other types of endoscopy, particularly nbi with magnification and autofluorescence to see if these techniques are helpful for discriminating between pre-cancerous and non pre-cancerous polyps. may 2007 protocol minor amendment: additional viewing by endoscopists outside st mark's ro allow assessment of inter- and intra-observer variability. no additional data collected.

Eligibility criteria:
inclusion criteria: * patients over 18 years of age, patients in a high risk group for adenomas exclusion criteria: * patients with known colitis or polyposis, unable or unwilling to give informed consent

Keywords: nbi high risk group for adenomas
histologic assessment of the difference between 18f-2-fluoro-2-deoxy_d-glucose positron emission mammography(pem) and magnetic resonance imaging (mri) of the breast

Conditions: Breast Cancer

Summary: positron emission mammography (pem) is a newly developed imaging examination of the breast that uses a radioactive glucose based tracer, which is a form of sugar attached to a low radiation agent, to detect cancer cells. the radioactive glucose based tracer is called fluorodeoxyglucose (fdg), and it is fda approved. a pem scanner is able to better detect cancer cells within the breast, more than a regular pet scanner. the pem scanner is also fda approved. this type of imaging may be able to see the breast cancer before it could be seen with mammograms and may be as good as or better than breast mri. the purpose of this study is to compare the value of fdg positron emission mammography (pem) with contrast enhanced magnetic resonance imaging (mri) of the breast for patients with breast cancer. this study will also perform special pathology test to compare the fdg pem and contrast enhanced breast mri images with the results from the standard of care breast surgery. this may teach us more about the biology of each breast tumor.


Eligibility criteria:
inclusion criteria: * female patients with recently diagnosed invasive or in situ breast cancer by core needle biopsy or fna (confirmed at mskcc) prior to enrollment. * patients planning treatment with mastectomy at mskcc. * patients 21 years old or older. * patients who had or are having a breast mri within 30 days or less of pem. * patients who had or are having a digital mammogram. exclusion criteria: * patients who are pregnant or breast feeding. * patients with prior radiation therapy or endocrine therapy. * patients who had a prior lumpectomy. * patients who are diabetic. * patients with moderate to end stage kidney disease. * patients who have a contraindication to mri (i.e. pacemaker, metallic implants, etc).

Keywords: mri pem 10-189
a study of duvelisib in participants with relapsed or refractory peripheral t-cell lymphoma (ptcl)

Conditions: Peripheral T-cell Lymphoma

Summary: this is a multi-center, parallel cohort, open-label, phase 2 study of duvelisib, an oral dual inhibitor of phosphoinositide-3-kinase-delta, gamma (pi3k-δ,γ), in participants with relapsed/refractory peripheral t-cell lymphoma (ptcl).

the study had 2 phases, a dose optimization phase and an expansion phase. in the dose optimization phase, participants were randomly assigned to 1 of 2 study cohorts, as follows: * cohort 1: duvelisib per oral (po) twice daily (bid) at a starting dose of 25 milligrams (mg), with potential escalation on a per-participant basis to 50 mg and then 75 mg, based on the participant's response to and tolerance of therapy, in 28-day cycles. * cohort 2: duvelisib 75 mg po bid, administered in 28-day cycles. a total of 20 participants were to be enrolled in the dose optimization phase, with 10 participants per cohort. based on the safety and activity data obtained in the dose optimization phase of the study, the expansion phase dose of duvelisib was to be determined. in the expansion phase, approximately 100-130 participants were to be enrolled and receive duvelisib dose in 28-day cycles as determined in dose optimization phase.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years of age 2. diagnosis of one of the following histologic subtypes of ptcl, pathologically confirmed, as defined by the world health organization: 1. peripheral t-cell lymphoma-not otherwise specified; 2. angioimmunoblastic t-cell lymphomas; 3. anaplastic large cell lymphoma (alcl); or 4. natural-killer/t-cell lymphoma 3. received at least 2 cycles of one standard regimen for newly diagnosed advanced ptcl, and one of the following: 1. failed to achieve at least a pr after 2 or more cycles of standard therapy; 2. failed to achieve a cr after completion of standard therapy; and/or 3. persistent or progressive disease after an initial response 4. for participants with cd30+ alcl, failed or are ineligible or intolerant to brentuximab vedotin 5. measurable disease as defined by lugano for ptcl, that is, at least 1 measurable disease lesion \> 1.5 centimeters in at least one dimension by conventional techniques (fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography \[ct\], ct with contrast, magnetic imaging resonance) exclusion criteria: 1. primary leukemic ptcl subtypes (that is, t-cell prolymphocytic leukemia, t-cell large granular lymphocytic leukemia, adult t-cell leukemia/lymphoma and aggressive nk-cell leukemia) or transformed mycosis fungoides 2. received prior allogeneic transplant 3. received prior treatment with a pi3k inhibitor 4. known central nervous system involvement by ptcl 5. ongoing treatment with chronic immunosuppressants (e.g., cyclosporine) or systemic steroids \> 20 mg of prednisone (or equivalent) once daily 6. ongoing treatment for systemic bacterial, fungal, or viral infection at screening 7. known hypersensitivity to duvelisib and/or its excipients

Keywords: lymphoma t-cell lymphoma relapse refractory pi3k-δ,γ
a pilot study of plasma renin activity guided vs generic combination therapy for hypertension

Conditions: Hypertension; Plasma Renin Activity

Summary: the purpose of this study is to investigate the effect of plasma renin activity-guided therapy for determining hypertension treatment. plasma renin is an enzyme in your blood that can be measured to determine your hypertension subtype. once the subtype is known, doctors can prescribe specific medications to target your specific hypertension subtype. this study will investigate whether targeting the specific hypertension subtype helps to achieve blood pressure control sooner and with fewer medications compared to a standard fixed dose combination therapy.


Eligibility criteria:
inclusion criteria: * systolic bp average during at least one recent (within 1 month) clinic or emergency room visit ≥ 150 mmhg, or diastolic bp average during at least one recent (within 1 month) clinic or emergency room visit ≥ 95 mmhg * not currently taking bp-lowering medication * clinician recommends pharmacologic treatment * willing to make necessary study visits * able to be contacted by phone * has a primary care clinician * at least 18 years old exclusion criteria: * known secondary cause of hypertension * pregnancy * known diabetes, coronary artery disease or renal disease * known sulfonamide allergy or history of gout * participant's clinician recommends he/she not enroll * hyponatremia, hypokalemia, hypernatremia, or hyperglycemia at baseline visit * baseline visit systolic visit bp average \< 140 mmhg and diastolic bp average \< 90 mm hg * resting heart rate \< 55 beats per minute
safety and effectiveness evaluation of two kinds of peritoneal dialysate

Conditions: Kidney Failure,Chronic

Summary: this study is to evaluate the effectiveness and safety of huaren peritoneal dialysate and baxter peritoneal dialysate, investigate the proper dialysis dose for chinese capd patients.

this study is a prospective, randomized, parallel, controlled, multi-center clinical study of huaren peritoneal dialysate and baxter peritoneal dialysate.it aims to investigate the proper dialysis dose for chinese capd patients.at the same time,it can evaluate the effectiveness and safety of chinese product huaren peritoneal dialysate and peritoneal dialysis product baxter peritoneal dialysate.

Eligibility criteria:
inclusion criteria: * age ≥18, male or female * patients with end stage renal diseases * dialysis mode: capd * dialysis duration:≥30 days and ≤6 months * be capable of implementing home dialysis * diabetic nephropathy, 3ml/min≤ residual renal gfr ≤15ml/min; other renal diseases, 3ml/min≤ residual renal gfr ≤10ml/min * sign the written informed consent exclusion criteria: * acute renal failure * planing to receive kidney transplantation in 2 years * hemodialysis * exit site infection or tunnel infection * presenting 2/3 of the following: a. abdominal pain, turbid ascites, with or without fever; b. drainage fluid wbc\>100×106/l, neutrophil ratio\>50%; c.culture positive/ gram stain positive in drainage fluid; * anti-hiv positive * allergic to components of dialysate * active, residual malignant tumor, or systemic infection, liver cirrhosis, severe congestive heart failure, anemia（hb\<80g/l）,malnutrition（serum alb\<28g/l）,refractory hypertension * identified peritoneal high transportation by peritoneal equilibration test (pet) * extreme body shape (height\> 185cm or height \<145cm), obesity (bmi ≥ 33kg/m2) * poor compliance * pregnant or lactating, women of childbearing age do not agree to use effective contraceptive measures during the trial * has a history of alcoholism and drug abuse (defined as illegal drugs) * any circumstances when patients are believed unsuitable for this trial

Keywords: capd efficacy safety survival rate
controlled randomized stimulation versus resection (corastir)

Conditions: Epilepsy

Summary: patients will be prospectively randomized to 3 different treatment arms: * treatment group 1: patients who undergo medial temporal lobe resection * treatment group 2: patients who receive immediate hippocampal neurostimulation * treatment group 3: patients who are implanted with an intracranial electrode but in whom hippocampal neurostimulation is delayed for 6 months. twelve months after inclusion unblinding will occur. patients in group 2 and 3 will have the option to choose between continuing neurostimulation treatment or resective surgery. study visits will occur every 3 months.


Eligibility criteria:
inclusion criteria: * presurgical candidates with pharmacoresistant partial seizures despite optimal medical treatment and history of temporal lobe epilepsy * age above 18 years * tiq \> 80 * able to give informed consent * average of 2 partial seizures per month during a baseline of 3 months. recording of seizures must have been done in a prospective manner using standard seizure diaries. * able to adequately report seizure frequencies using standard seizure diaries * video-eeg characteristics showing temporal lobe seizure onset (left-sided or right-sided seizure onset) in at least one recorded habitual seizure * presence of a structural abnormality in the medial temporal lobe, suggestive of hippocampal sclerosis as evidenced by optimum mri * women of child-bearing age will be required to use a reliable method of contraception during the study duration exclusion criteria: * extratemporal epilepsy; multifocal epilepsy; evidence of bilateral medial temporal lobe epilepsy * mr evidence of potentially epileptogenic lesions outside the medial temporal lobe such as dysplasias, tumours or cavernomas * prior resective intracranial surgery * patients who are candidates for invasive video-eeg recording or have previously been investigated with invasive video-eeg recording * patients who previously underwent any other type of neurostimulation for treating epilepsy * patients who are unable to fill in questionnaires and comply with protocol requirements * progressive neurological or medical conditions * medical or psychiatric conditions precluding surgery or compliance * patients taking antidepressant medication * pregnancy at study onset * previous (within the last 3 months), ongoing or planned participation in other treatment study protocols for epilepsy * contraindication for intracranial surgery
compare of prp autologous serum and autologous serum by intrastromal injection in different eye disease conditions

Conditions: PRP

Summary: platelet-rich plasma (prp) is an autologous blood product rich in proteins and growth factors. its application has been the subject of many studies in the field of ophthalmology to stimulate tissue healing and regeneration. due to its anatomical features (lack of blood vessels), the cornea is among the most susceptible to damage structures of the eye. therefore, the study of the impact of various regenerative therapies (autologous blood products, serums, ) on corneal lesions is important not only scientifically, but also practically for ophthalmologist. numerous reports described the healing effect of prp on corneal lesions.

purpose the objective of the study is to compare the efficacy of 100% prp autolog serum eye drops with 100 % of intrastromal injection-rich plateles plasma autolog serum eye drops in patients with moderate to severe dry eye in keratoconus disease,corneal dystrophy,chemical burns. methods a total of 40 eyes were included in this prospective study. clinical records of 20 consecutive patients with dry eye disease who had been treated with conventional autolog eye drops via intrastromal injection(conventional treatment group) and 20 consecutive patients treated with intrastromal autologous prp eye drops i(prp eye drops treated group) from september 2021.

Eligibility criteria:
inclusion criteria: * dry eye diseases from other conditions( diabetes,allergy,keratoconus and others) * corneal dystrophy * chemical burns * keratoconus exclusion criteria: * hemoglobin saturation (less than 11 mg/dl); * hepatopathies; * nephropathies; * coagulopathies; * hemoglobinopathies; * decompensated heart diseases; * infectious diseases such as chagas, syphilis, hiv, htlv, hepatitis b and c, and others transmissible by blood considered.

Keywords: prp dry eye keratoconus dystrophy regenerative therapy
a study of ly3437943 in healthy participants and participants with impaired renal function

Conditions: Healthy; Renal Insufficiency

Summary: the main purpose of this study is to assess the amount of study drug that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to healthy participants. the study will last up to 5 weeks, excluding screening.


Eligibility criteria:
inclusion criteria: normal participants: * healthy male and female participants as determined by physical examination * participants with normal renal function assessed by estimated glomerular filtration rate (egfr) ≥ 90 milliliter per minute (ml/min). * body mass index (bmi) ≥ 19.0 and ≤ 40.0 kilograms per meter squared (kg/m²) * male participants who agree to use contraception and female participants of child bearing potential must agree to use contraceptive methods and women not of child bearing potential can participate. participants with renal impairment: * have acceptable blood pressure (bp) and pulse rate, as determined by the investigator * participants with type 2 diabetes must have a glycated hemoglobin (hba1c) ≥ 5.0% and ≤ 11.5% * are males or females with severe renal impairment as determined by a stable egfr \<30 ml/min, not requiring hemodialysis or * are males or females with end-stage renal disease (have received hemodialysis for at least 3 months) exclusion criteria: * have known allergies to ly3437943 or related compounds * have a current, functioning organ transplant. nonfunctional renal allografts may be allowed * have any abnormality in the 12-lead electrocardiogram (ecg) * are women with a positive pregnancy test or women who are lactating
safety and antiviral study of ach-126, 443 (beta-l-fd4c) in the treatment of adults with hiv infection and modestly detectable viral load.

Conditions: HIV Infections

Summary: to determine safety and efficacy of ach-126,443 on the treatment of adults with hiv infection who have modestly detectable viral load while on stable triple combination antiretroviral therapy including 3tc.


Eligibility criteria:
inclusion criteria: * adults ≥18 years of age * receiving a stable triple combination antiretroviral regimen including 3tc, one other nrti and either an nnrti or a protease inhibitor for at least 4 months (16 weeks) * demonstration of initial viral suppression and subsequent rebound to be defined as an initial virological drop of at least 0.5 logs on a 3tc-containing regimen * plasma hiv rna level \> 1000 and \< 30,000 copies/ml on two occasions * genotypically documented m184v variant of hiv rt * clinically stable hiv status with no aids-defining events * cd4 \> 200 cells/mm3 * basic hematologic and chemistry parameters within acceptable limits (defined in protocol) * all women of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity of 25 iu/l of b-hcg) within 72 hours prior to the start of study medication * no active opportunistic infection requiring treatment * subject must be able to provide written informed consent * baseline laboratory values measured within 28 days of initiating study drug as follows: * hgb≥9.0g/dl or hct≥27% (in the absence of blood transfusions or erythropoietin treatment in the preceding two weeks * absolute neutrophil count≥1000 cells/mm(\^3) (in the absence of on-going g-csf therapy * platelet count ≥75,000/mm(\^3) * ast \<7.0 times the upper limit of normal * alt ,7.0 times the upper limit of normal * serum creatinine \<1.1 times the upper limit of normal exclusion criteria * evidence of active hbv infection as demonstrated by hbsag positivity * hepatitis c co-infection * concurrent systemic antiviral treatment * previous therapy with agents with significant systemic myelosuppressive or cytotoxic potential within 3 months of study start or the expected need for such therapy at study start. * alcohol abuse * pregnancy or breast-feeding * inability to tolerate oral medication * ast \> 7.0 times the upper limit of normal * alt \> 7.0 times the upper limit of normal * any clinical condition or prior therapy that, in the investigators opinion, would make the subject unsuitable for the study or unable to comply with the dosing requirements. * use of any other drug or substance with anti-hbv activity

Keywords: treatment experienced, stable triple anti-retroviral combination therapy in hiv-infected, achillion